≥99% PURITY GUARANTEED•THIRD-PARTY TESTED•SAME-DAY SHIPPING USA•FREE SHIPPING $200+•
Menu
≥99% Purity
Same-Day Ship
COA Included
GLP1-S - 5 mg
Popular Peptides

GLP1-S

GLP-1 receptor agonist research peptide studied in metabolic-pathway research.

$45.00
99.75% Purity Verified

Third-Party Tested by Verum Analytics

Batch: BIL-BATCH-01-2602Feb 26, 2026
+99% Purity
Third-Party Tested
COA Available
31 sold in the last 24 hours
Order in 0h 0min for same-day shipping
Buy More, Save More
QuantityPrice
Add 2 more for 15% off
$45.00
Albert - Chief Researcher

Albert's Verdict

GLP1-S operates on the same receptor as the most clinically validated metabolic drugs in history, but in a research peptide format. The beta-cell preservation and gastric motility data make this one of the most referenced compounds in our metabolic category.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL
99%+ PurityThird-Party Verified
Same-Day ShippingOrder by 2PM EST
Satisfaction Guarantee

Product Description

GLP1-S is a GLP-1 receptor agonist research peptide investigated in laboratory research models of incretin signaling and metabolic pathways. It binds to GLP-1 receptors in laboratory models studying glucose-dependent cellular signaling.

Molecular Profile:

  • Classification: GLP-1 Receptor Agonist
  • Target: GLP-1R (Glucagon-Like Peptide-1 Receptor)
  • Mechanism: Incretin mimetic with extended half-life

Research Applications:

  • Glucose-dependent insulin-signaling research models
  • Beta-cell cellular research models
  • Incretin-pathway research models
  • Gastric-emptying pathway research models
  • Cardiovascular cellular research models
  • Neuroprotective pathway research models

Quality Standards:

  • Purity: ≥99% verified by HPLC
  • Third-party tested with COA included
  • Lyophilized powder form

For laboratory handling instructions, refer to the Preparation Guide. Published trial dosing information from external literature is provided separately on the Literature References page and is not product-use guidance.

FOR RESEARCH USE ONLY. Not for human or animal consumption.

Technical Specifications

Molecular Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol
Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$122.00

Research FAQ — GLP1-S

Frequently asked questions about this compound for laboratory researchers.

What is Semaglutide / GLP-1-S?+
Semaglutide is a GLP-1 receptor agonist research peptide. Published trial literature describes its pharmacology, glycemic effects in T2D research populations, and outcomes from the STEP and SUSTAIN trial families.
Cited: PMID 33567185, PMID 31185157
What does STEP-1 research data show?+
The STEP-1 publication (NEJM, 2021) describes once-weekly Semaglutide 2.4 mg versus placebo in research subjects with overweight or obesity over 68 weeks. The trial reports body-weight endpoints as its primary outcome.
Cited: PMID 33567185
How is Semaglutide dosed in published research?+
Published trial protocols administer Semaglutide once weekly via subcutaneous injection. Dose-titration schedules from 0.25 mg up to 2.4 mg are commonly reported. Refer to the cited literature and your IRB protocol.
Cited: PMID 33567185
How is Semaglutide stored?+
Lyophilized Semaglutide stores at −20 °C protected from light. Reconstituted solution is refrigerated at 2–8 °C and typically used within 28 days. Refer to the product COA.

Published research references

Peer-reviewed literature relevant to GLP1-S research. Linked PubMed IDs open the original source.

  1. [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — N Engl J Med (2021) · PMID 33567185
  2. [2]Semaglutide and cardiovascular outcomes in obesity without diabetes — N Engl J Med (2023) · PMID 34882832
  3. [3]Effect of Subcutaneous Semaglutide vs Placebo on Cardiovascular Outcomes (SUSTAIN-6) — N Engl J Med (2016) · PMID 31185157
BL
Reviewed by the BioInfinity Research Team
Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.
For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Learn More About This Peptide

GLP1-S Research Summary →Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.